CurrentCareSourcePolicy N/A

UTILIZATION MANAGEMENT MEDICAL POLICY

Defines prior authorization, coverage criteria, dosing limits, and prescribing requirements for Vonvendi (recombinant von Willebrand factor) for treatment of von Willebrand disease (VWD) under medical benefit. Includes approved indications (on-demand, perioperative, routine prophylaxis), dosing ceilings, duration of approval, and exclusions.

Policy Summary

PayerCareSource

PolicyUTILIZATION MANAGEMENT MEDICAL POLICY

Policy CodePolicy N/A

Change TypeAnnual revision — no criteria changes

Effective Date

Next Review Date

Key ActionPrior Authorization is recommended for Vonvendi; approve patients who meet criteria and dosing, and refer doses outside policy to clinician review.

SourceLink

POLICY UPDATE CHANGES

Annual Revision dated 12/04/2024 with no criteria changes.

3Approved Indications (on-demand, perioperative, routine prophylaxis)

900 IU/kgMax single/28-day dosing for on-demand/perioperative

60 IU/kgMax dose for routine prophylaxis (per administration)

1 yearTypical authorization duration

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Scope: This policy defines prior authorization, coverage criteria, dosing limits, and prescribing requirements for Vonvendi (recombinant von Willebrand factor) for treatment of von Willebrand disease (VWD) under the medical benefit. Vonvendi is covered with criteria for on-demand treatment, perioperative management, and routine prophylaxis in severe Type 3 VWD when other criteria are met. The agent must be prescribed by or in consultation with a hematologist.

Coverage stance and criteria summary: Approval is recommended when the patient has a diagnosis of VWD and the agent is prescribed by or in consultation with a hematologist. For on-demand treatment and perioperative management, dosing is allowed up to a ceiling of 900 IU/kg intravenously no more frequently than once every 28 days. For routine prophylaxis in patients with severe Type 3 VWD previously treated on-demand, dosing is allowed up to 60 IU/kg intravenously no more frequently than twice weekly. Requests for doses outside these limits will be reviewed case-by-case by a clinician.

Authorization duration: Typical authorization is for 1 year when prescribed by or in consultation with a hematologist. The policy also allows for individualized dosing and provides for prophylactic therapy plus additional acute/perioperative coverage (prophylactic plus three days of acute/perioperative management per 28 days) consistent with dosing considerations.